Gardner: CBT-I Safer, More Effective Than Drugs for Chronic Insomnia at Forum 2026
“Now is the time for us to be all together on this, to be a part of the transformation of insomnia management from pharmacologic to nonpharmacologic approaches,” said David Gardner, PharmD, professor of psychiatry at Dalhousie University in Halifax.
Cognitive-behavioral therapy is safer and more effective than sleep medications for chronic insomnia and is now readily available through self-guided apps, according to a presentation delivered at the Family Medicine Forum 2026, medscape.com reported. Chronic insomnia involves difficulty initiating or maintaining sleep on at least 3 nights per week for 3 or more months.
Healthcare providers should wean patients from sleep medications such as sedatives when they no longer need them, David Gardner, PharmD, professor of psychiatry at Dalhousie University in Halifax, told medscape.com. Short-term sleep hygiene techniques like avoiding devices before bedtime usually do not significantly affect chronic insomnia.
Patients with severe insomnia can benefit from setting a regular bedtime and rise time while using the bed only for sleep, sickness, and sex. But cognitive behavioral therapy for insomnia, an evidence-based 4- to 8-week program involving cognitive and behavioral strategies, provides an effective alternative, Gardner said.
The therapy teaches patients to adapt habits and change thought patterns that interfere with a good night’s sleep. While the approach previously required trained therapists, self-guided apps and programs make it increasingly accessible.
Gardner suggests physicians and patients examine the nonprofit Sleepwell program, which functions as a one-stop shop for available apps and aims to help patients improve sleep and stop taking sleeping pills safely. The platform receives funding from the Drug Evaluation Alliance of Nova Scotia and the government of Nova Scotia.
Finding effective alternatives matters because prescriptions for sleep medications increase steadily as patients age into their eighties and nineties. Gardner said that vulnerability to side effects is greatest in older, frailer adults.
Pharmaceutical sleep aids carry risks including falls, fractures, cognitive impairment, and flu-related pneumonia resulting from immune system effects. Drugs fail to treat the underlying cause of chronic insomnia.
Researchers comparing the benzodiazepine temazepam with a placebo found that time to sleep initiation was 11 minutes shorter according to polysomnography and 7 minutes shorter according to self-assessment, said Stephanie Lynch, PharmD, a pharmacist and research lead at Queen’s University in Belleville-Quinte, Ontario, medscape.com reported. The medication was also associated with 21 more minutes of sleep.
Clinicians can reduce reliance on sleep aids by avoiding initial prescriptions, preventing dose escalations, and deprescribing, Lynch said. Deprescription involves discussing why patients take the aid, its perceived effectiveness, and any side effects.
Managing insomnia can also involve a sleep diary to document sleep timing, overnight awakenings, daytime naps, and the use of alcohol, cannabis, and sleep medications. Guylène Thériault, MD, a family doctor in Gatineau, Quebec, told medscape.com that CBT-I should serve as the default option for patients with severe insomnia.
Research shows that the number needed to treat with CBT-I is three. Thériault, who has practiced for 30 years and did not learn about the therapy in medical school, called that success rate huge compared with pharmaceutical treatments.
Thériault said that useful resources and deprescribing schedules also appear at the Canadian Medication Appropriateness and Deprescribing Network and Choosing Wisely Canada. While switching patients off long-term benzodiazepines presents challenges, she emphasized that the transition is a discussion worth having.
“I have to offer CBT-I to three patients for one of them to have success, which is huge,” MD said.